Recombinant Human FGFR2(IIIb) protein (hFc Tag, Myc Tag, His Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
hFc Tag, Myc Tag, His Tag
Activity
not tested
Cat no : Eg0175
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <1.0 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human FGFR2(IIIb) protein Arg22-Glu378 (Accession# P21802-3) with a human IgG1 Fc tag, a Myc tag and a His tag at the C-terminus. |
| GeneID | 2263 |
| Accession | P21802-3 |
| PredictedSize | 71.1 kDa |
| SDS-PAGE | |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
FGFR2 (Fibroblast growth factor receptor 2) is a tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration, and apoptosis. Ligand binding leads to the activation of several signaling pathways, such as RAS, MAPK1/ERK2, MAPK3/ERK1, and the MAP Kinase signaling pathway, as well as the AKT1 signaling pathway. Mutations in the gene of FGFR2 are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. This polyclonal antibody raised against 358-704aa of human FGFR2 can cross-react with other members of the FGFR family.
References:
1. Vogel, Arndt et al. Annual review of medicine vol. 74 (2023): 293-306. 2. Goyal, Lipika et al. The New England journal of medicine vol. 388,3 (2023): 228-239. 3. Subbiah, Vivek et al. Cancer discovery vol. 13,9 (2023): 2012-2031. 4. Zingg, Daniel et al. Nature vol. 608,7923 (2022): 609-617.